Ruth Backer - 10X Genomics Chief Officer
| TXG Stock | USD 13.29 0.03 0.23% |
Insider
Ruth Backer is Chief Officer of 10X Genomics
| Age | 47 |
| Address | 6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260 |
| Phone | 925 401 7300 |
| Web | https://www.10xgenomics.com |
10X Genomics Management Efficiency
The company has Return on Asset of (0.1137) % which means that on every $100 spent on assets, it lost $0.1137. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2487) %, meaning that it generated no profit with money invested by stockholders. 10X Genomics' management efficiency ratios could be used to measure how well 10X Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.28. The current Return On Capital Employed is estimated to decrease to -0.33. At this time, 10X Genomics' Intangibles To Total Assets are most likely to slightly decrease in the upcoming years. The 10X Genomics' current Debt To Assets is estimated to increase to 0.12, while Non Current Assets Total are projected to decrease to roughly 210.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Annie McGuire | Veracyte | 43 | |
| David Liu | Beam Therapeutics | N/A | |
| Darya Chudova | Guardant Health | 50 | |
| Mark DVM | Fate Therapeutics | 63 | |
| Giuseppe Ciaramella | Beam Therapeutics | 55 | |
| Suzanne Fleming | Beam Therapeutics | 63 | |
| Edward III | Fate Therapeutics | 48 | |
| Nicole Gaudelli | Beam Therapeutics | N/A | |
| Aaron Sato | Twist Bioscience Corp | N/A | |
| MS MBA | Fate Therapeutics | N/A | |
| Tracy Morris | Veracyte | N/A | |
| Craig MD | Guardant Health | 57 | |
| YuWaye MD | Fate Therapeutics | N/A | |
| Brian Riley | Beam Therapeutics | 47 | |
| Andy Ament | Guardant Health | N/A | |
| Kumud Kalia | Guardant Health | 58 | |
| Erin Smith | Twist Bioscience Corp | N/A | |
| Alexis Komor | Beam Therapeutics | N/A | |
| Feng Zhang | Beam Therapeutics | N/A | |
| TerryAnn MBA | Beam Therapeutics | 47 | |
| John MBA | Beam Therapeutics | 46 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.11 |
10X Genomics Leadership Team
Elected by the shareholders, the 10X Genomics' board of directors comprises two types of representatives: 10X Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 10X. The board's role is to monitor 10X Genomics' management team and ensure that shareholders' interests are well served. 10X Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 10X Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Wilbur, Chief Officer | ||
| Mennah Moustafa, Chief Officer | ||
| Ruth Backer, Chief Officer | ||
| Florian Baumgartner, Senior Manager | ||
| Jonathan Schimmel, VP Operations | ||
| James Bryant, Director Legal | ||
| Jim Goodrich, Chief Operations | ||
| Benjamin Hindson, President, CoFounder | ||
| Eric Esq, Chief Officer | ||
| Cassie Corneau, Manager Finance | ||
| Adam Taich, Treasurer, CFO | ||
| Justin McAnear, Chief Officer | ||
| Jim Wilbur, Chief Officer | ||
| Jens Durruthy, Associate Management | ||
| Alexander Wong, Chief Officer | ||
| Michael SchnallLevin, Founding CTO | ||
| Serge Saxonov, CEO CoFounder | ||
| Rebecca Port, Chief Officer | ||
| Nikhil Rao, Director Management |
10X Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 10X Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 1.3 B | ||||
| Shares Outstanding | 107 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 94.38 % | ||||
| Number Of Shares Shorted | 7.61 M | ||||
| Price To Book | 2.23 X |
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 5.261 | Quarterly Revenue Growth (0.01) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.